Last reviewed · How we verify
KUS121 high dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
KUS121 high dose (KUS121 high dose) — Kyoto Drug Discovery and Development Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KUS121 high dose TARGET | KUS121 high dose | Kyoto Drug Discovery and Development Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- KUS121 high dose CI watch — RSS
- KUS121 high dose CI watch — Atom
- KUS121 high dose CI watch — JSON
- KUS121 high dose alone — RSS
Cite this brief
Drug Landscape (2026). KUS121 high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/kus121-high-dose. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab